These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 20039404

  • 1. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
    Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A.
    Arthritis Rheum; 2010 Jan; 62(1):201-10. PubMed ID: 20039404
    [Abstract] [Full Text] [Related]

  • 2. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Belimumab Study Group.
    Arthritis Res Ther; 2008 Jan; 10(5):R109. PubMed ID: 18786258
    [Abstract] [Full Text] [Related]

  • 3. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW, BLISS-52 Study Group, BLISS-76 Study Group.
    Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
    [Abstract] [Full Text] [Related]

  • 4. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 5. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I.
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [Abstract] [Full Text] [Related]

  • 6. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1168-78. PubMed ID: 19714604
    [Abstract] [Full Text] [Related]

  • 7. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008 Sep 15; 9(3):197-202. PubMed ID: 18457473
    [Abstract] [Full Text] [Related]

  • 8. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, Zickert A, Mikeš J, Achour A, Amara K, Piehl F, Brodin P, Gunnarsson I, Malmström V.
    EBioMedicine; 2019 Feb 15; 40():517-527. PubMed ID: 30593436
    [Abstract] [Full Text] [Related]

  • 9. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 15; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 10. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr 15; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 11. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J, Furie R.
    Lupus; 2013 Apr 15; 22(4):361-71. PubMed ID: 23553779
    [Abstract] [Full Text] [Related]

  • 12. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR.
    BMJ Open; 2019 Dec 16; 9(12):e032569. PubMed ID: 31848169
    [Abstract] [Full Text] [Related]

  • 13. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS.
    Ann Rheum Dis; 2018 Jun 16; 77(6):883-889. PubMed ID: 29563108
    [Abstract] [Full Text] [Related]

  • 14. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus.
    Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG.
    Ann Rheum Dis; 2013 Jan 16; 72(1):118-28. PubMed ID: 22858586
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.
    Ann Rheum Dis; 2016 Feb 16; 75(2):332-40. PubMed ID: 26293163
    [Abstract] [Full Text] [Related]

  • 16. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients.
    Rodríguez-Bayona B, Ramos-Amaya A, Pérez-Venegas JJ, Rodríguez C, Brieva JA.
    Arthritis Res Ther; 2010 Feb 16; 12(3):R108. PubMed ID: 20525218
    [Abstract] [Full Text] [Related]

  • 17. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.
    Ann Rheum Dis; 2008 Jul 16; 67(7):1011-6. PubMed ID: 17962238
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ.
    Ann Rheum Dis; 2016 Feb 16; 75(2):323-31. PubMed ID: 26338095
    [Abstract] [Full Text] [Related]

  • 19. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.
    Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J.
    Arthritis Res Ther; 2019 Nov 29; 21(1):259. PubMed ID: 31783909
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 29; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.